20-F: Bon Natural Life Reports FY2025 Net Loss Amid Revenue Decline

Bon Natural Life Limited reported a significant net loss for fiscal year 2025, driven by a substantial decrease in total revenue and gross profit, despite strategic shifts in product focus and recent capital raises.

Summary

• Total revenue for fiscal year 2025 decreased by 21.7% to $18,670,684 from $23,844,556 in fiscal year 2024.
• The company recorded a net loss of $2,049,431 in fiscal year 2025, a significant decline from a net income of $345,248 in fiscal year 2024.
• Gross profit decreased by 45.4% to $3,878,821 in fiscal year 2025, with the gross margin falling to 20.8% from 29.8% in the prior year.
• Sales volume of health supplemental powder drinks decreased by 49.2% in FY2025, reflecting reduced market demand and a strategic shift.
• Sales volume of fragrance compound products increased by 218.8% in FY2025, but average selling price decreased by 48.7%.
• Sales volume of bioactive food ingredients increased by 55.7% in FY2025, but average selling price decreased by 61.7% due to fierce market competition.
• Operating expenses increased by 5.1% to $5,502,036 in fiscal year 2025, primarily due to increased share-based selling and general & administrative expenses.
• The company completed a public offering in March 2025, raising $12 million in gross proceeds, and a private offering in May 2024, raising $5.6 million.
• A 1-for-25 reverse stock split was approved by shareholders on April 15, 2025, and became effective on May 19, 2025.
• The company faced Nasdaq delisting concerns in May 2025 due to minimum bid price non-compliance and significant dilution from the March 2025 offering, but was granted continued listing with a one-year monitoring period.
• Xin Ma was appointed as the new Chief Financial Officer on November 12, 2025, replacing Wallace Lee who resigned.
• The company authorized a share repurchase program of up to $1 million of its Class A ordinary shares on May 31, 2025.
• Material weaknesses in internal control over financial reporting were identified, related to a lack of accounting staff with U.S. GAAP and SEC reporting knowledge, with remedial measures in progress but not fully addressed.

Sentiment

Score: 3

Explanation: The company experienced a significant decline in revenue and a shift to net loss in FY2025, coupled with decreasing gross margins. While strategic shifts and capital raises are underway, the financial performance indicates substantial challenges and operational headwinds. The identified material weaknesses in internal controls and past Nasdaq compliance issues add to the negative sentiment, despite efforts to address them.

Positives

• Sales volume for fragrance compound products increased by 218.8% in fiscal year 2025, indicating strong demand for these specific products.
• Sales volume for bioactive food ingredients increased by 55.7% in fiscal year 2025, reflecting strong market demand in health and wellness sectors.
• The company successfully raised $12 million in gross proceeds from a public offering in March 2025, providing capital for expansion.
• Nasdaq granted the company's request for continued listing, resolving immediate delisting concerns, albeit with a monitoring period.
• The company possesses advanced bio-manufacturing technologies, which it believes offer higher yield and efficiency compared to traditional methods used by competitors.
• A first-mover advantage is identified in the rapidly expanding human micro-biome health market, a key focus for future product development.
• The company has a stable supply chain for raw materials and advantages in cost control due to its bio-manufacturing technology.
• Xian App-Chem was listed as a key enterprise during the COVID-19 pandemic for immunity-boosting products, granting preferential governmental and regulatory support.

Negatives

• Total revenue decreased by 21.7% in fiscal year 2025 compared to 2024, and by 19.2% in 2024 compared to 2023, indicating a sustained downward trend.
• The company reported a net loss of $2,049,431 in fiscal year 2025, a significant reversal from net income in previous years.
• Gross profit decreased by 45.4% in fiscal year 2025, and the gross margin declined by 9.0% to 20.8%, primarily due to changing product mix and downward price adjustments.
• Sales volume of health supplemental powder drinks decreased by 49.2% in fiscal year 2025 due to reduced market demand and strategic reallocation of sales efforts.
• Operating expenses increased by 5.1% in fiscal year 2025, with selling expenses up 61.5% and general and administrative expenses up 28.9%, partly due to share-based compensation.
• A $1 million provision for doubtful accounts was recorded in fiscal year 2024 related to an acquisition deposit, reflecting uncertainty in recovery.
• The company identified material weaknesses in internal control over financial reporting due to a lack of accounting staff with U.S. GAAP and SEC reporting experience, which are not yet fully addressed.
• The company faced Nasdaq delisting concerns due to minimum bid price non-compliance and significant dilution from a recent offering.

Risks

• The business is subject to complex and rapidly evolving laws and regulations in China, with significant government oversight and discretion that could materially change operations or stock value.
• Potential delisting from U.S. stock exchanges if the auditor is not subject to PCAOB inspection for two consecutive years under the HFCAA, although the current auditor is U.S.-based and inspected.
• Failure to appropriately respond to changing consumer preferences and demand for new products or product enhancements could harm customer relationships, sales, and financial results.
• Production difficulties, quality control problems, inaccurate forecasting, and reliance on third-party suppliers could harm the business, including raw material availability and quality issues.
• Products have not been clinically proven safe or effective by regulatory agencies, and adverse reactions or negative publicity could harm the business.
• Increased competition from new and existing firms with greater capital resources, technology, and sales networks could cause market share and profitability to decline.
• Inability to obtain substantial additional financing (estimated $30 million for expansion) would impair the ability to execute the business plan.
• Loss of key personnel, particularly founder and CEO Mr. Hu, or inability to hire new qualified personnel, could substantially affect financial condition and prospects.
• Negative publicity about the company, its services, management, or practices could harm brand, reputation, and stock price.
• Uncertainties with the PRC legal system, including inconsistent interpretation and enforcement of laws, could adversely affect the company.
• Difficulties in effecting service of legal process, enforcing foreign judgments, or bringing actions in China against the company or management due to location and legal system differences.
• Limitations on the ability of PRC subsidiaries to distribute dividends to the holding company due to PRC regulations, statutory reserves, and capital controls, affecting the ability to fund cash and financing requirements.
• PRC regulation of loans and direct investment by offshore holding companies may delay or prevent the use of offering proceeds for capital contributions to PRC subsidiaries.
• Classification as a PRC resident enterprise for tax purposes could result in unfavorable tax consequences, including higher enterprise income tax and withholding taxes on dividends and gains for non-PRC shareholders.
• Uncertainty regarding indirect transfers of equity interests in PRC resident enterprises by non-PRC holding companies could lead to additional tax liabilities.
• Revocation or unavailability of preferential tax treatments and government subsidies, or successful challenges by PRC tax authorities, could increase tax liabilities.
• Failure to fully comply with PRC labor-related laws (e.g., social security, housing provident funds) and construction-related laws could expose the company to penalties, fines, or operational disruptions.
• The trading price of shares may fluctuate significantly due to market, industry, and company-specific factors, potentially resulting in substantial losses for investors.
• As a foreign private issuer, the company is exempt from certain U.S. securities rules and Nasdaq corporate governance standards, potentially affording less protection to shareholders.
• Certain judgments obtained against the company by shareholders may not be enforceable due to the company's incorporation in the Cayman Islands and primary operations in China.

Future Outlook

Management intends to use future earnings for research and development, new product development, and expansion of production capacity, and does not anticipate paying cash dividends in the foreseeable future. The company plans to expand its plants, improve technology, optimize the supply chain, and broaden sales channels, aiming for a compound annual growth rate of no less than 30% in its raw materials and ingredients business. Rapid expansion is planned for the functional health business, focusing on innovative products for human micro-biome health.

Management Comments

• Management believes that its bio-manufacturing technology gives it an average cost advantage in producing natural ingredients.
• Management is committed to achieving a compound annual growth rate in the raw materials and ingredients business line of no less than 30%.
• Management believes the high technical barriers to entry in its field will provide a three to five year lead against potential competitors.

Industry Context

The company operates in the natural products and ingredients industry, focusing on personal care ingredients, natural health supplements, and bioactive food ingredients. This industry is characterized by rapid changes in consumer trends, particularly in weight management, targeted nutrition, and immune health. The rapid development of human micro-biome technology is driving growth and attracting attention from large-scale food and ingredient companies, potentially increasing competition. The global COVID-19 pandemic has heightened consumer and public administrator focus on basic health issues, especially immune health, which aligns with the company's focus on human micro-biome adjustment and control.

Comparison to Industry Standards

• The company's ambroxide products are produced with 99.5% purity and above, compared to an industry average of approximately 99.0%.
• The yield of the company's ambroxide production is approximately 63%, significantly higher than the estimated industry average yield of 40% to 43%.
• The company's bio-technique for ambroxide production involves a six-step process in a mild environment, contrasting with competitors' chemical synthesis methods that typically involve 10 lengthy and complex steps.
• The company's continuous process for stachyose production, utilizing bio-enzyme and bio-membrane separation, is believed to lead to higher yield and purity compared to the traditional resin separation approach used by most competitors.
• Competitors like Chenguang Biotech, Layn, Koninklijke DSM N.V., Symrise AG, and Givaudan SA are noted for their stronger business scale, capital strength, larger sales networks, and brand recognition, posing competitive challenges.

Management Changes

Corporate Governance

Legal Proceedings

• Currently not a party to any material legal or administrative proceedings. May be subject to various legal or administrative claims in the ordinary course of business, which could result in substantial cost and diversion of resources.

Related Party Transactions

• As of September 30, 2025, the balance of due to related parties was $134,073, primarily from borrowings from related parties for working capital, which are non-interest bearing and due on demand.
• As of September 30, 2025, the balance of due from related parties was $527,389, mainly comprising advances to employees for business purposes, investment receivables, unreimbursed expenses, and petty cash.
• Controlling shareholder Mr. Yongwei Hu pledged his personal bank savings and, jointly with his wife Ms. Jing Liu, their personal residence property as collateral to guarantee the company's short-term and long-term bank loans.

Stakeholder Impact

• Shareholders: Experienced significant dilution from recent offerings and a reverse stock split. The net loss and declining revenue could negatively impact share price and investment returns. The dual-class share structure, if approved, will concentrate voting power with the CEO.
• Employees: The company continues to invest in R&D and sales teams, but the overall financial downturn could create uncertainty. Management changes, such as the new CFO, may bring new strategic directions.
• Customers: Strategic shifts in product focus (e.g., away from health supplements) and downward price adjustments in other segments could impact customer relationships and product availability.
• Suppliers: Changes in purchasing volumes and strategic shifts in product mix could affect supplier relationships, although the company aims for a stable supply chain.
• Creditors: The company has significant outstanding bank loans, and its ability to renew these loans is crucial for liquidity. The pledge of personal assets by the CEO and his wife provides some security for certain loans.

Next Steps

• Invest internally generated cash and capital raised to add additional teams to the direct sales force.
• Expand geographic reach with new distribution channels into other provinces within China and overseas.
• Establish more sales online.
• Accelerate business growth and market expansion, leveraging rapid industrial advancements in information technology and life science technology.
• Actively seek opportunities for collaboration and cooperation with large-scale enterprises focused on human micro-biome-related businesses (e.g., Guangzhou Wanglaoji Pharmaceutical, JDB, Wahaha, Mengniu, Yili, Chr. Hansen).
• Continue implementing remedial measures to address material weaknesses in internal control over financial reporting, including hiring qualified accounting personnel and establishing an internal audit function.
• Monitor ongoing compliance with Nasdaq continued listing requirements under the Discretionary Panel Monitor for one year.
• Renew existing bank loans upon maturity based on past experience and good credit history.
• Urge the landlord of the Weinan Raw Materials and Ingredients Production Site to apply for relevant permits and handle procedures for buildings constructed without proper permits, or consider relocating production.

Key Dates

Recommendation

The company faces significant financial headwinds, evidenced by a substantial net loss and declining revenue and gross profit in FY2025. While strategic shifts towards higher-demand product categories and recent capital raises provide some liquidity and a foundation for future growth, the execution risk remains high. The identified material weaknesses in internal controls and ongoing competitive pressures in the Chinese market warrant caution. The Nasdaq continued listing, while positive, comes with a monitoring period. Investors should hold existing positions to observe the effectiveness of the company's strategic adjustments and remediation efforts, particularly in improving profitability and internal controls, before considering further investment or divestment.

Keywords

Natural Products, Bioactive Food Ingredients, Fragrance Compounds, Health Supplements, China Operations, SEC Filing, 20-F, Financial Performance, Corporate Governance, Risk Factors, Nasdaq, Biotechnology, Nutritional Supplements, Personal Care Ingredients, Human Micro-biome